Surveyed U.S. Oncologists Indicate They Would Prescribe Medivation/Astellas Pharma`s Enzalutamide to 30 Percent of Their Second- and Third-Line Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients